uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Treatment of focal hyperhidrosis with botulinum toxin type A:  Brief overview of methodology and 2 years' experience
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences. (Dermatology and Venereology)
1999 (English)In: European Journal of Neurology, ISSN 1351-5101, E-ISSN 1468-1331, Vol. 6, no Suppl 4, s117-s120 p.Article in journal (Refereed) Published
Abstract [en]

Focal hyperhidrosis is a relatively common condition in which patients experience excessive sweating, usually of the palms, axillae, face or feet. Until recently, the only effective treatment option for this chronic condition was surgery. We aimed to evaluate the efficacy and tolerability of botulinum toxin type A (BTX-A) in the treatment of patients with hyperhidrosis, establishing optimum dosages and methods of administration. One hundred and seventy patients with focal hyperhidrosis were referred for treatment, the majority with palmar and axillary hyperhidrosis. The iodine-starch test was used to locate and show the extent of the hyperhidrotic area. Using a template to mark the injection sites, 2 U doses of BTX-A were injected intradermally at regular intervals. Patients received either 0.5 or 0.8 U/cm2 with regional anaesthesia if required. The iodine starch test and measurements of evaporation were used to assess efficacy. The majority of patients reported a marked reduction in sweating, About one-third of the patients who received BTX-A 0.5 U/cm2 requested supplementary small injections into islands of skin where they experienced residual sweating. As a result, the standard dose was increased to BTX-A 0.8 U/cm2. The median duration of treatment effect was 10 months (range, 3 to >14 months). The effectiveness of BTX-A was not reduced by repeated use. BTX-A treatment was well tolerated by all patients. In conclusion, chemical sudomotor denervation with BTX-A should be recommended before surgical sympathectomy for the treatment of focal hyperhidrosis.

Place, publisher, year, edition, pages
1999. Vol. 6, no Suppl 4, s117-s120 p.
Keyword [en]
yperhidrosis, excessive sweating, botulinum toxin type A, palms, axillae
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-54507DOI: 10.1111/j.1468-1331.1999.tb00028.xOAI: oai:DiVA.org:uu-54507DiVA: diva2:82416
Available from: 2008-10-17 Created: 2008-10-17 Last updated: 2017-12-04Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text
By organisation
Department of Medical Sciences
In the same journal
European Journal of Neurology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 334 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf